Knowledge-Based Therapeutics for Tricarboxylic Acid (TCA) Cycle-Deficient Cancers
Daniel Peled1, Ruth Casey2, Eyal Gottlieb3
1Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa 3525433, Israel.
Cold Spring Harbor Perspectives in Medicine
|March 19, 2024
Summary
Cancer metabolism research has uncovered key mutations in enzymes like succinate dehydrogenase, leading to harmful oncometabolite accumulation. This work updates knowledge on tumor biochemical mechanisms and future clinical directions.
Area of Science:
- Oncology
- Biochemistry
- Metabolic pathways
Background:
- Otto Warburg's foundational work established early concepts of cancer metabolism.
- Recent research has expanded understanding of cancer's unique metabolic circuitry.
- Mutations in conserved cellular pathways are implicated in tumorigenesis.
Purpose of the Study:
- To reflect on recent advancements in cancer metabolism research.
- To update knowledge on the biochemical mechanisms driving tumors.
- To provide rationale for ongoing clinical trials and anticipate future research directions.
Main Methods:
- Review of recent literature on cancer metabolism.
- Analysis of mutations in key metabolic enzymes.
- Elucidation of oncometabolite accumulation and function.
Main Results:
- Identification of specific mutations in tricarboxylic acid cycle enzymes, including succinate dehydrogenase and fumarate hydratase.
- Understanding the role of oncometabolites in cancer progression.
- Illumination of the unique metabolic reprogramming in cancer cells.
Conclusions:
- Cancer metabolism is a complex field with significant recent advancements.
- Understanding oncometabolites offers potential therapeutic targets.
- Continued research is crucial for developing novel cancer treatments.
More Related Videos
07:53Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
11.1K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Tumor Immunotherapy
524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
02:34Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K